Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing

This article was originally published in The Pink Sheet Daily

Executive Summary

The traditional pattern of Japanese firms outlicensing their products for the West is shifting as the U.S. market looks increasingly appealing compared to Japan’s price controls and sagging economy. Major Japanese pharmas have been building U.S. development capability, resulting in a full pipeline of products to be developed and marketed directly in the U.S.

You may also be interested in...



The Quality Lowdown: Corporate Culture And Site Complexity Can Pose Challenges

Quality and the measure of a firm: Toyobo’s particulates and resins, Galenicko’s sanitation, Breckenridge’s product chemistry and Fujifilm’s cross-contamination risk.

Optimer Eyes Early 2010 Debut For Diarrhea Meds

Prulifloxacin proves positive in Phase III and early results for soon-to-end OPT-80 study look good, CEO says.

Optimer Eyes Early 2010 Debut For Diarrhea Meds

Prulifloxacin proves positive in Phase III and early results for soon-to-end OPT-80 study look good, CEO says.

Related Content

Topics

UsernamePublicRestriction

Register

PS060440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel